References
- Prozialeck WC. Update on the pharmacology and legal status of kratom. J Am Osteopath Assoc. 2016;116:802–809.
- Prozialeck WC, Jivan JK, Andurkar SV. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc. 2012;112:792–799.
- Anwar M, Law R, Schier J. Notes from the field: Kratom (Mitragyna speciosa) exposures reported to poison centers - united states, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65:748–749.
- Griffin OH, Webb ME. The scheduling of kratom and selective use of data. J Psychoactive Drugs. 2018;50:114–120.
- U.S. Food and Drug Administration. FDA and kratom [Internet]. Silver Spring (MD): U.S. Food and Drug Administration. [updated 2018 Feb 26; cited 2018 Oct 23]. Available from: https://www.fda.gov/newsevents/publichealthfocus/ucm584952.htm
- Drug Enforcement Administration. Drugs of abuse: a DEA resource guide [Online]. Arlington (VA): Drug Enforcement Administration, U.S. Department of Justice; 2017. [cited 2018 Oct 23]. Available from: https://www.dea.gov/sites/default/files/sites/getsmartaboutdrugs.com/files/publications/DoA_2017Ed_Updated_6.16.17.pdf#page=84
- Grundmann O. Patterns of kratom use and health impact in the US-results from an online survey. Drug Alcohol Depend. 2017;176:63–70.
- Pain News Network. Kratom survey [Internet]. La Crescenta (CA): Pain News Network; 2018. [cited 2018 Oct 23]. Available from: https://www.painnewsnetwork.org/kratom-survey/
- Smith KE, Lawson T. Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program. Drug Alcohol Depend. 2017;180:340–348.
- Warner ML, Kaufman NC, Grundmann O. The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. Int J Legal Med. 2016;130:127–138.
- Cumpston KL, Carter M, Wills BK. Clinical outcomes after kratom exposures: a poison center case series. Am J Emerg Med. 2018;36:166–168.
- Kapp FG, Maurer HH, Auwarter V, et al. Intrahepatic cholestasis following abuse of powdered kratom (Mitragyna speciosa). J Med Toxicol. 2011;7:227–231.
- Ulbricht C, Costa D, Dao J, et al. An evidence-based systematic review of kratom (Mitragyna speciosa) by the natural standard research collaboration. J Diet Suppl. 2013;10:152–170.
- U.S. Food and Drug Administration. Statement from FDA commissioner Scott Gottlieb, M.D., on the agency’s scientific evidence on the presence of opioid compounds in kratom, underscoring Its potential for abuse [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2018. [updated 2018 Apr 5; cited 2018 Oct 23]. Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm595622.htm
- American Association of Poison Control Centers. National poison data system (NPDS): NPDS coding users’ manual version 3.1 [Online]. Alexandria (VA): American Association of Poison Control Centers; 2014. [cited 2018 Oct 23]. Available from: https://aapcc.s3.amazonaws.com/pdfs/member-resources/NPDS_Coding_Users_Manual_v3.1_07May2014.pdf
- Boyer EW, Babu KM, Adkins JE, et al. Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction. 2008;103:1048–1050.
- Tavakoli HR, Buchholz AC, Kabir IK, et al. Kratom: an emerging drug of abuse. Emerg Med. 2017;49:209–214.
- Mackay L, Abrahams R. Novel case of maternal and neonatal kratom dependence and withdrawal. Can Fam Physician. 2018;64:121.
- Trakulsrichai S, Tongpo A, Sriapha C, et al. Kratom abuse in ramathibodi poison center, Thailand: a five-year experience. J Psychoactive Drugs. 2013;45:404–408.
- Matsumoto K, Mizowaki M, Suchitra T, et al. Central antinociceptive effects of mitragynine in mice: contribution of descending noradrenergic and serotonergic systems. Eur J Pharmacol. 1996;317:75–81.
- Nelsen JL, Lapoint J, Hodgman MJ, et al. Seizure and coma following kratom (Mitragynina speciosa korth) exposure. J Med Toxicol. 2010;6:424–426.
- Neerman MF, Frost RE, Deking J. A drug fatality involving kratom. J Forensic Sci. 2013;58(1):S278–S279.
- FDA Consumer Health Information. FDA 101: dietary supplements [Internet]. Silver Spring (MD): U.S. Food and Drug Administration. [updated 2015 Jul 15; cited 2018 Oct 23]. Available from: https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm050803.htm
- Borchardt JK, Ohio could soon ban plant-based supplement used to treat pain, opioid addiction [Internet]. Cincinnati (OH): Cincinnati Enquirer; 2018. [updated 2018 Oct 2; cited 2018 Oct 23]. Available from: https://www.cincinnati.com/story/news/2018/10/01/ohio-could-soon-ban-kratom-products/1491649002/
- Bergen-Cico D, MacClurg K, Chapter 89 - kratom (Mitragyna speciosa) use, addiction potential, and legal status. In: Preedy VR, editor. Neuropathology of drug addictions and substance misuse. San Diego (CA): Academic Press; 2016. p. 903–911.
- Kronstrand R, Roman M, Thelander G, et al. Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend krypton. J Anal Toxicol. 2011;35:242–247.
- Lydecker AG, Sharma A, McCurdy CR, et al. Suspected adulteration of commercial kratom products with 7-hydroxymitragynine. J Med Toxicol. 2016;12:341–349.
- U.S. Food and Drug Administration. Statement from FDA commissioner Scott Gottlieb, M.D. and FDA deputy commissioner for foods and veterinary medicine Stephen Ostroff, M.D., on the ongoing risk of salmonella in kratom products [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2018. [updated 2018 Jul 2; cited 2018 Oct 23]. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm612420.htm